PKU Patient Enzyme Activator

My Take: A novel intervention that directly activates the enzyme deficitent in PKU

Name: Sephience (sepiapterin)

Class: Phenylalanine hydroxylase activator (metabolic enzyme activator) for phenylketonuria (PKU).

Usefulness: Treats phenylketonuria (PKU) in both children and adults by enhancing the activity and stability of the phenylalanine hydroxylase (PAH) enzyme. Lowers blood phenylalanine levels and reduces the dietary restrictions faced by PKU patients.

Method of Action: Activates the PAH enzyme, which is deficient or dysfunctional in PKU, facilitating the breakdown of phenylalanine and preventing its harmful accumulation in the body.

Potential Market: PKU occurs in about 1 in 15,000 U.S. newborns and has limited treatment options. Projected peak sales of around $741 million by 2030.

Competing Agents: Existing treatments include:

• Kuvan (sapropterin), a synthetic BH4 cofactor

• Palynziq (pegvaliase), an injectable enzyme substitution therapySephience offers a novel oral small-molecule mechanism, which may provide improved ease-of-use and adherence.

Cost to Consumer: As an orphan drug, it will likely be priced comparably or potentially higher than Kuvan and Palynziq, with copay assistance programs probable to support patient access.

Unusual Fact: One of the few enzyme activators approved to treat a genetic metabolic disorder, which are usually managed by dietary therapies, cofactor replacement, or enzyme substitution.